Objectives-For improved thrombolysis therapy based on ultrasound irradiation, researchers and practitioners would strongly benefit from an easy and efficient in vitro assay system of thrombolysis activity involving irradiated ultrasound. For the present study, we designed a new in vitro sonothrombolysis assay system using a sheet-type clot.
I n the present-day therapies for acute ischemic strokes, a critical need is present for better prognosis. 1 Among these therapies, recombinant tissue plasminogen activator (rt-PA) intravenous injection therapy is the first choice, and its effectiveness has been proven. 2 However, accompanying this therapy is a considerably high ratio of symptomatic intracerebral hemorrhages (eg, 4-8% in typical definitions) among the rt-PA-injected patients. [3] [4] [5] [6] Reduction of this hemorrhage ratio is strongly desirable, and higher therapeutic efficiency resulting in improved prognosis is no less desirable.
To achieve these reductions and improvements, researchers have examined a combinatory therapy of ultrasound irradiation alongside rt-PA injections. [7] [8] [9] [10] [11] [12] Irradiation of ultrasound can enhance rt-PA's thrombolysis activity in several mechanisms 11 : There can be an increase in rt-PA's permeation in fibrin networks, 13, 14 an increase in rt-PA's binding sites on fibrin, 15 and a disaggregation of fibrin networks. 16 Moreover, induced cavitation [17] [18] [19] enhances thrombolysis in two ways: stable cavitation and inertial cavitation. Stable cavitation 13, [20] [21] [22] accelerates rt-PA's transport in a periodic manner for a sustained period, whereas inertial cavitation 17, 22 can trigger both jetting (directional high-speed conventional transport driven by collapsed bubbles) and the mechanical destruction of fibrin networks. 23, 24 Therefore, elucidation of the underlying mechanism through measurements of sonothrombolysis merits further investigation.
Because many physical parameters (eg, frequency, acoustic intensity, pulse width, and duty cycle) influence thrombolytic activity, precise and facile in vitro assay methods pertaining to thrombolytic effects are important in the optimization of these many ultrasound parameters for sonothrombolysis. In a conventional and simple method, sonothrombolysis is assayed through measurements of a blood clot's mass. 19, 25, 26 Alternatively, amounts of lysed (dissolved) proteins (eg, ddimer, hemoglobin, fibrin) in an aqueous phase are measured according to a photometric method 27, 28 or a radioisotope method. 29, 30 The direct mass measurement method is simple and easily done without any special instrument; however, its disadvantage is a risk of considerable error when liquid is wiped off a solid clot. The method involving dissolved protein measurements is free from this "wipe-off" error. Both of these methods, despite their strengths, include the following disadvantages. First, experimental measures of thrombolysis activities are dependent on the size and shape of clots. A lysis-induced weight-loss ratio is dependent on a ratio of surface area to volume. Accordingly, a lysed weight loss ratio can be larger when the clot diameter is smaller. Therefore, different assays' rates of thrombolysis cannot be compared with one another among direct mass measurement methods. Furthermore, if a clot is large enough to receive a different ultrasound field in each point, measured thrombolysis values must be the average of all of the points and all ultrasound field strengths.
Cheng et al 31 reported a novel measurement method using a glass micropipette tubing container and a microscope. Because of their use of microscopy, they could observe the thrombolysis over time at a single point. Petit et al 32 analyzed clot-diameter decreases by using another microscopy-based method. With it, they could conduct a one-time measurement of sonothrombolysis activity at many points, and could obtain the correlations between thrombolysis enhancements and ultrasound field strength (also in a one-time measurement). They observed the thrombolysis enhancements in the presence of both rt-PA and microbubbles. However, an "rt-PA only" condition with sonication could not yield thrombolysis enhancement even in strong ultrasound irradiation conditions (1000 kPa in peak acoustic pressure, and 11 W/cm 2 in average intensity). We try to establish an alternative method to measure sonothrombolysis activity at many points in one time measurement.
In addition to the disadvantages of the previously reported methods, there is a potential problem with the formation of standing waves due to ultrasound reflection at cells and containers of clots. This type of wave forms resulting from interference between advancing waves and reflection waves, and the formation of standing waves is very dependent on geometrical factors 33 of experimental setups. Once standing waves are formed, stronger spots and weaker spots than the advancing waves are alternatively and repeatedly distributed along the propagating direction. Distance between a stronger spot and a weaker spot is a quarter of the wavelength of the irradiated ultrasound when ultrasound enters a flat surface vertically. The emergence of the standing waves makes it impossible to obtain close relationships between thrombolysis behaviors and ultrasound conditions. In many reports of sonothrombolysis measurements, standing-wave formation was handled only by means of a water tank, and was suppressed typically by means of ultrasonic absorbing material positioned in the tank. These previous reports did not address the standing-wave formation inside clot cells and clot containers. In the current study, we are the first to examine standing wave formation inside clot cells.
To resolve these problems with the reported methods, we have developed a new in vitro assay method of sonothrombolysis using a sheet-type clot. We can measure a change in a clot's thickness spectroscopically. Because of this methodology, we can easily obtain many data points of one clot in one time measurement. This method should help us to analyze the correlations between sonothrombolysis activity and ultrasound conditions.
Previously, we reported a prototype clot-measurement method 34 using a bovine sheet-type fibrin clot. We succeeded in determining bovine fibrin clots' thickness by measuring the optical density of a sheettype clot, and applied this method for assays of ultrasound's inhibition effects on the clots' growth in vitro. However, in this prototype method, clot thickness was observed to increase during measurements. This clot-thickness increase (ie, clot growth) was unfavorable for measurements of clot-lysis caused by rt-PA. Additionally, in the prototype method, dispersion of measured data was not small enough to obtain exact relationships between rt-PA's clot lysis activity and irradiated-ultrasound intensity. The reason for the large dispersion was unknown in the previous article. 34 In this paper, we have substantially improved this prototype method, to measure rt-PA's clot-lysis activity and obtain these correlations. Through our improvements, we found instances of constant clot thickness in an untreated control group during measurements. Then, we assumed the reason for the large dispersion in the prototype method was the ultrasound's reflection in clot cells, and examined favorable designs of the clot cells. Additionally, we made a new insight into rt-PA's clotlysis measurement. Namely, we examined standing-wave formation in clot cells. We will discuss the standing waves' possible effects on the lysis measurements in this study. As illustrated in Figure 1 , the reduced thickness (ie, lysis length) of the clot after sonication can be measured at many data points on one disk in one time measurement. Consequently, the relationships between ultrasound conditions and the lysis length can be obtained easily from these many data points. The aim of our study is to establish a new, easy, and efficient sonothrombolysis measurement method for optimization of ultrasound irradiation parameters. Moreover, we have succeeded in preparing a fibrin-clot sheet from human plasma. In our previous report, we used a clot sheet made from bovine plasma. Clot-sheet preparation from human plasma is generally more difficult than clot-sheet preparation from bovine plasma, because human plasma's properties are more heterogeneous than bovine plasma's.
In summary, we believe that this new thrombolysis assay method is very useful for the fundamental analyses of ultrasound's thrombolysis enhancement effects.
Materials and Methods

Cell Containing Fibrin Clot
We made a clot cell with a pair of aluminum frames (outer size: 80 3 80 mm; inner window size: 50 3 50 mm). As shown in Figure 2A , one frame was 1-mm thick and was used as the cover frame, and the other frame was 2-mm thick and was used as the body frame. As shown at the top of Figure 2B , a polymer film was adhered to the cover frame as the front wall. On the body-frame side, a 1-mm-thick silicone insert sheet and a polymer film were adhered to the body frame. We examined the effects of film thickness on standing-wave formation in this clot cell by using 500-lm-thick polycarbonate film, 200-lm-thick polystyrene (PS) film, 50-lm-thick PS film, and 25-lm-thick polypropylene (PP) film. After the examinations, we chose a 25-lm-thick PP film that served as the front wall, and a 50-lm-thick PS film that served as the back wall. Consequently, for our clot-lysis experiment, we obtained a space having a depth of 3 mm and an area of 50 3 50 mm. To prepare a 4-mm-deep clot cell, we placed another 1-mm-thick aluminum insert at the upper side of the body frame, as shown at the bottom of Figure 2B . We used these two types of cells (3-mm-deep and 4-mm-deep) according to the purposes of the given experiments.
Clot Preparation
Frozen citrated human plasma (Product No. 12250110) was purchased from Kohjin-Bio (Saitama, Japan), thawed at 37 C, filtered with a glass microfiber filter (GF/D: 2.7 lm, 47 mm, Whatman Ltd, Kent, UK), dispensed in a tube, and stored at 2308C. Bovine thrombin (T-4648, Sigma-Aldrich Co, St. Louis, MO) was A PP film with an area of 40 3 40 mm was adhered to a 1.5-mm-thick silicone insert, which was fixed with four acryl-made propping bars. The propping bars were placed on the body frame as shown in Figure 2C . Consequently, a 1.5-mm-thick gap was made between the PP film and the PS film of the body frame. In some experiments, we used a thinner 1.0-mm-thick silicone spacer (in the space of the standard 1.5-mm-thick silicone spacer), to prepare a thicker clot. In these cases, we obtained a 2.0-mm-thick gap for clot formation. A large clot with a side length of approximately 40 mm and a thickness of 1.0-2.0 mm was used in this study. This side length was much bigger than the photometric measurement area diameter (12 mm). We chose this large clot to avoid possible edge effects. One of the possible edge effects is that the clot edge forming a boundary with solution may cause reflection of ultrasound.
We thawed frozen human plasma and bovine thrombin solutions at 37 C. Then, we degassed the thawed human plasma at 240 kPa for 15 min at room temperature to prevent air-bubble formation in the clot-preparation process, and diluted the bovine thrombin solution at 20 NIH units/mL with 0.1% BSA. We mixed the human plasma with a 0.4-M CaCl2 solution (final concentration 20 mM) and the bovine thrombin solution (final concentration 1 NIH unit/ml) in a propylene centrifuge tube, and swiftly pipetted the mixed solution into the space between the PP and PS films as shown in Figure 2C . We incubated the obtained mixture for 10 min at room temperature, and then for 90 min at 378C in a humid atmosphere (in a temperature-controlled chamber with an open-air water container). After the incubation, we obtained a uniform sheet-type clot on the PS film base by removing the PP film (the silicone insert and propping bars were removed together). We obtained clots in a thickness range from 1.2 to 1.5 mm in the standard preparation with a 1.5-mmthick silicone insert, whereas thicknesses of clots prepared with a thinner 1.0-mm-thick silicone insert ranged from 1.7 to 2.0 mm. 
Sonothrombolysis Setup
We prepared an rt-PA solution according to a manufacturer's instructions (GRTPA inj. 6 million IU, Mitsubishi Tanabe Pharma Corp, Osaka, Japan) at 600,000 IU/mL (1000 lg/mL). We diluted the rt-PA solution at 1.0 lg/ mL with a Tween tris-buffered saline solution that contained 0.1 w/v% Tween 80 (Sigma-Aldrich, St. Louis, MO) and 20 mM Trizma7.5 (T2319, Sigma-Aldrich, St. Louis, MO) in saline. We filled the diluted rt-PA solution in the clot cell that contained an approximately 1.5-mm-thick clot. Then, we swiftly attached a cover frame to a body frame, as shown in Figure 2A . We set this cell in a water bath as shown in Figure 3A . The set cell was sonicated with an insonation transducer. The base of the water bath was lined with 2 layers of 10-mm-thick ultrasound adsorbing rubber tiles (EUA201A, Eastek Corp., Tokyo, Japan), and the water was degassed with a water degasser (3502W, ERC Inc., Saitama, Japan) and temperature-controlled at 37 6 0.58C with a temperature controller (TJA-500P, AS ONE Co, Osaka, Japan). We used two sonication probes. One was custom-made by Honda Electronics Co, Ltd, (Toyohashi, Aichi, Japan) with a circular planar footprint having a diameter of 10 mm. Oriented for in vitro and animal experiments, this probe was unfocused and possessed a center frequency of 500 kHz. Although the probe could not send ultrasounds deep enough for human-brain applications, it could emit intensities greater than 5 W/cm 2 . We call this Probe A, and its ultrasound irradiation at 50 kHz occurred in a continuous wave manner at 4.5 W/cm 2 (Pr 5 0.36 MPa). The second probe was model PU0031, manufactured by Ueda Japan Radio Co, Ltd, (Ueda, Nagano, Japan). This probe (which we named Probe B) possessed a circular planar and an unfocused transducer having a diameter of 24 mm with a nominal frequency of 500 kHz and a broad bandwidth ranging from 357 to 665 kHz (6-dB down). Probe B was oriented for human applications and could send ultrasound deep into the human brain. In contrast, Probe B could emit only an intensity of less than 1 W/cm 
Clot-Thickness Measurement
Ultrasound-based enhancements of rt-PA's thrombolysis activity were measured by the use of a sheet-type clot and a spectrophotometric method. Clot thickness before and after sonothrombolysis was measured with a custom-made spectrophotometer (JASCO Corp, Tokyo, Japan). An illustration of this custom-made spectrophotometer is shown in Figure 4 . This photometer had an automatic XY stage to hold the cell body and could automatically draw an optical density map of a clot. A photodetector with an integrating sphere collected light passing and reflecting through or at a clot. The diameter of the integrating sphere's aperture was either 2 or 12 mm. Because of a function of the integrating sphere, we were able to obtain high photosensitivity for a small measured area of a clot. The clot was scanned in 4 radially directed tracks with a length of 1.2 cm, as shown in Figure 3B , at a rate of approximately 4 points/s. We examined absorption spectra in a range from 300 to 800 nm to determine the best wavelength for the clot thickness measurement in terms of high sensitivity and stable measurements. After obtaining the wavelengthexamination results (described in the "Results" section), we set the light wavelength at 560 nm, with a bandwidth of 10 nm and a beam diameter of 0.5 mm. Before conducting the sonication, we measured a fibrin clot on the body frame. After the sonication, the cover frame was removed, the fibrin clot was rinsed twice with saline, and the clot on the body frame was measured. A measured optical density value was converted to the clot's thickness according to a calibration curve. To prepare a calibration fibrin clot exhibiting a linear change of thickness, we used a wedge-shaped chamber, as shown in Figure  5A . In this wedge-shaped chamber, we obtained a thickness from 0 to 3.1 mm. In measuring a calibration clot in this wedge-shaped chamber, we conducted the scanning in a parallel direction as shown in Figure 3C , and we used the averages of the two parallel tracks' values for a calibration curve between optical density and clot thickness. Figure 5B presents an x-ray computed tomography (CT) image of the clot prepared between two 200-lmthick PS films in this wedge-shaped chamber. This CT image indicates that the clot was formed without any defect and was the exact same size and shape as the size and shape (length 42 mm, thickness 0-3.1 mm) of the space made in the wedge-shaped chamber. Because of this exactness, we were able to obtain a plot of the optical density and thickness of the clot. Enhanced lysis length and enhanced ratio are defined as follows:
Enhanced lysis length 5 (thickness change at the center*) 2 (thickness change at 6 mm from the center*)
Enhanced ratio 5 {(thickness change at the center*) -(thickness change at 6 mm from the center*)}/(thickness change at 6 mm from the center*) 3 100% *The 'center' refers to a position in the cell vertically below the midpoint of a transducer.
Choice of Measurement Wavelength
We planned to measure the thickness of the fibrin clot by means of spectroscopy. For this measurement, we prepared a custom-made spectrometer that would determine optical density at small spots of a clot in a rapid scanning manner. First, we measured an optical-density spectrum at one spot (a 1.5-mm-thick point) of a human fibrin clot in the calibration chamber. A fibrin clot was observed to exhibit an optical density spectrum as shown in Figure 6A . We compared the three spectra with a clotting period of 60, 140, and 210 min at 378C, and found no change among the three clotting periods (the green, light blue, and blue lines completely overlapped). Therefore, we prepared a clot with a 90-min clotting period at 378C. Figure 6A plots the plasma mixture: Human plasma made up 90% of the mixture's total volume, and saline made up the remaining 10%. In other words, the plasma concentration of the mixture was the same as the plasma concentration of the clot. Across the whole range of measured wavelengths, we observed higher opticaldensity values of the clot than we did for 90% of the plasma, and this difference in the optical density probably resulted from increased turbidity due to clot formation.
Initially, for the current study's measurement we tried to use an optical density value at 412 nm, where we found a peak in a spectrum of 90% plasma, and where we found a shoulder in a spectra of the clots, as shown in Figure 6A . Then, we measured the spectrum change when a clot was incubated in saline. Figure 6B presents results of our 60-min and 120-min incubation cases. There was a very slight increase in the optical density except in an area near the 460-nm wavelength. To analyze more closely the differences between the spectrum change at a wavelength of approximately 460 nm and the spectrum changes at the other wavelengths, we performed the same measurements using a 12-mm diameter aperture in the spectrum detector, whereas we used a 2-mm diameter aperture in all other experiments of the study. In our measurements of the optical density of the clot, we measured both the solid clot's molecular absorption of proteins and the solid clot's turbidity. With this wider aperture, the molecular absorption's contribution to the optical absorbance became greater than the contribution for the narrower (2 mm) aperture case. Figure 8C presents results concerning the wider aperture. We noted that the optical density ranging from 400 to 470 nm decreased considerably during the incubation of the clot in saline, whereas after making the same measurements of the clot in saline at a wavelength of 560 nm, we found only a slight change for a 2-h incubation. These results indicate that some proteins exhibiting optical density at 412 nm exuded from the fibrin clot network into saline, and that optical density at 560 nm was scarcely changed because the 560-nm optical-density value was obtained as a result of the turbidity of the solid clot, not to molecular absorption of proteins included in the clot. Consequently, we chose 560 nm for the measurement wavelength. Even though an optical density coefficient at 560 nm was smaller than one at 412 nm, measurements of optical density at 560 nm were free from the effects of exuding proteins. These results indicate that optical density at 560 nm accurately determines a clot's thickness by means of the clot's turbidity.
Comparison of Our Method With the Clot-Mass Method
We can reveal characteristics of our spectrophotometric method by comparing it with a conventional clot-mass measurement method. For this comparison, we prepared a fibrin clot of approximately 100 mg in the clot cell shown in Figure 3 . We put 150 lL of human plasma mixed with the thrombin solution into the clot cell, and obtained a fibrin clot of approximately 100 mg. In the clot preparation for the clot-mass method, we used a PP film (10 3 10 mm) that was smaller than the PP film used for the spectrophotometric method shown in Figure 3C . We incubated the prepared clot in an rt-PA solution in the same manner as that described for the sheettype clot, except we used a shorter incubation period (15 min) for the rt-PA incubation. A PS film adhering to the clot was cut into a piece almost the same size of the clot. We measured the weight (of the clot plus the piece Figure 6 . Choices for measuring wavelengths. Spectra of human fibrin clots measured at a 1.5-mm-thick point in a calibration chamber. Effects of clotting period at 378C on spectra (A). Change in spectra during the incubation of a clot in saline (B). Change in spectra during the incubation of a clot in saline measured through a 12-mm-diameter aperture (C).
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Optical density of PS film) after rinsing the clot once with saline and then wiping off excess liquid with Kimwipe S-200 paper (Nippon Paper CRECIA Co, Ltd, Tokyo, Japan). We repeated this measurement 3 times pre-and post-rt-PA incubation. After the final weight measurement, we removed the PS film from the clot, and measured the film's weight. Then, we obtained weights of the clot by subtracting the PS film's weight from the total weight (the weight of the PS film plus the weight of the clot). For the sheet-type clot, the rt-PA incubation was conducted in the absence of ultrasound irradiation for 30 min. To determine the thickness of the sheet-type clot, we repeated spectroscopic measurements 3 times after rinsing the clot with saline each time.
Measurements of the Ultrasound Field in the Clot Cell
To examine the effects that the front and back wall films and the other parts of the clot cell had on the ultrasound field, we used two methods: one with a hydrophone and the other with a Schlieren imaging system. Measurements with a hydrophone were performed with the ultrasound Probe B (explained in the "Sonothrombolysis Setup" subsection under "Materials and Methods"), an Acoustic Intensity Measurement System (AIMS) (NTR Systems, Inc, Seattle, WA), and a hydrophonepreamplifier set (HNC-0400, active diameter: 0.4 mm, Onda Corporation, Sunnyvale, CA). For this hydrophone, special-order calibration was made in a Figure 7 . Cell-size effects on ultrasound acoustic intensity with Probe B. Clot-cell-dependent acoustic intensity (A). Two-dimensional map of "no cell" case (B). Two-dimensional map of "24 3 26 mm clot cell" case (the same grey-scale specifications as those in Figure 4B ) (C). Twodimensional map of "50 x 50 mm clot cell" case (the same color specifications as those in Figure 4B ) (D). Ultrasound may reflect at the cell frame, and the reflected ultrasound may interfere with nonreflected ultrasound. We used Probe B in the hydrophone measurement to examine the reflected ultrasound's interference because we surmised that the interference would be more severe for Probe B than for Probe A. Probe B is wider in diameter than Probe A, and Probe B generates an ultrasound beam wider than the one generated by Probe A. The clot cell without any film was set perpendicular to the beam axis at a distance of 43.0 mm from the footprint of the probe to the base of the cell. We scanned the ultrasound field at 42.0 mm below the footprint of the probe, finding that the measured field was located 1.0 mm above the cell base. This location was a position of the thrombolytic frontier of a clot. The ultrasound irradiation was driven by a 500 kHz sine wave of 71.2 Vpp (peak-to-peak voltage).
The second method involved a Schlieren imaging system (Mizojiri Optical, Tokyo, Japan) consisting of a water tank, a light source, a pinhole, a pair of highquality optical lenses, a ring knife edge, and a chargecoupled-device camera. The lenses had a diameter of 25 cm and a focal length of 150 cm. The diameter of the ring knife-edge was 1.3 mm. Ultrasound irradiation was performed with Probe A (explained in the "Sonothrombolysis Setup" subsection under "Materials and Methods") at a driving voltage of 15 Vpp. Probe A was used in the Schlieren measurement to get a high signal-to-noise ratio with an acoustic intensity that would be stronger than the one associated with Probe B. With this Schlieren system, we observed standing waves forming between two plastic walls. Because standing waves of 500-kHz ultrasound can generally be observed with bright and dark stripes at 1.5-mm intervals, we created a gap between the two walls at 7.0 mm (as shown in Figure 6 ). With this gap, we expected to observe a 4-stripe contrast. Using an acryl-made film holder and two plastic films (500-lm-thick polycarbonate film, 200-lm-thick PS film, 50-lm-thick PS film, or 25-lm-thick PP film), we fixed the two films to the holder (there was a 7.0-mm-wide gap between the two films).
Statistical Analysis
We performed a statistical analysis of the data by using the unpaired two-sided Student's t-test. A P-value < .05 indicated statistical significance.
Results
Measurements of the Ultrasound Field in the Clot Cell
Because any type of clot cell possesses walls that surround fibrin clots, reflection of ultrasound at these walls may change the ultrasound's field in the cell. In particular, standing waves constitute an important factor influencing the change. Standing waves can be generated from interference between advancing waves and other waves reflecting at these walls. Evasion of standing-wave generation is favorable for correct evaluation of sonothrombolysis through close relationships between an enhancement of rt-PA's thrombolysis capability and ultrasound's field strength. We succeeded in obtaining a reflection-effect-free and standing-wave-effect-free cell for sonothrombolysis measurements by improving the size of the cell and the thickness of films. Figure 7A shows profiles of ultrasound's acoustic field intensity measured with a hydrophone when 500-kHz ultrasound was irradiated by the use of Probe B at 0.70 W/cm 2 (at the center irradiation position) with a driving voltage of 71.2 Vpp. The ultrasound's field-intensity profile of a small clot cell with a 24 3 26 mm window area (red plots) was observed to clearly diverge from that of the "no cell" case (black plots). This divergence indicates undesirable effects of ultrasound's reflection in this small cell. After making this observation, we prepared a cell having larger dimensions (a 50 3 50 mm window area), and observed differences less than 3% between the ultrasound's intensities of the large-cell case and those of the "no cell" case. Figure 7B -D, compare twodimensional acoustic-intensity profiles of Figure 7A 's three cases. An acoustic profile of the large clot cell case ( Figure 7D ) was close to that of the "no cell" case ( Figure 7B ), whereas the profile of the small clot cell case ( Figure 7C ) substantially differed from that of the "no cell" case. All of these facts indicate that the effects of reflection on the ultrasound's field-strength profile were negligible for the large cell.
Standing waves were observed in Schlieren images with a contrast between bright stripes and dark stripes in a film-thickness-dependent manner, as shown in Figure 8 . In Schlieren images, dark stripes are generally found at positions representing maximum acoustic pressure, whereas bright stripes are found at positions representing no acoustic pressure. (The change rate of acoustic pressure differentiated by position, not by time, is maximum with bright stripes, whereas the change rate is zero with dark stripes.) There was no change between a Schlieren image of the no-holder, no-film case ( Figure 8A ) and that of the holderonly case ( Figure 8B ). In contrast, both the polycarbonate film case (500-lm thick on both the front and back walls, Figure 8C ) and the polystyrene film case (200-lm thick on both the front and back walls, Figure 8D ) distinctly exhibited the presence of standing waves, as seen in their strong contrasts. After observing these standing waves, we used a thinner PS film (50-lm thick) for the back wall and a thin PP film (25-lm thick) for the front wall. As shown in Figure 8E , standing waves were greatly reduced with these thin films. For quantitative comparisons of standing waves, our previous paper defined a ratio representing degrees of standing waves, R SW . 35 R SW was defined as R SW 5 (B local max 2 B local min ) Ave/ B mean , where B local max , B local min , and B mean are the local maxima, the local minima, and the mean of the brightness, respectively. The R SW value of Figure 8E (50-lm-thick PS film plus 25-lm-thick PP film) was 0.05. This value was much smaller than the 0.40 value in Figure 8C (500-lm-thick PC films) and the 0.31 value in Figure 8D (200-lm-thick PS films).
Measurements of Fibrin-Clot Thickness by Means of Spectroscopy
In preparing human fibrin clots for the current study's spectroscopic measurement, we encountered two problems that we had not identified in our previous study with bovine fibrin clots. 34 The first problem was the heterogeneous status of citrated human plasma. The purchased citrated human plasma for the current study was turbid, whereas the bovine plasma used in the previous study had been transparent. When the human plasma was filtered through a common 0.45-lm-diameter filter, the filter was quickly clogged. This clogging might significantly filter out some important proteins for clot formation. After observing the clogging in the current study, we used a glass microfiber filter with a pore size (2.7 lm) that was larger than the previous filter's, and we found that a transparent filtrate was very smoothly obtained. The second problem encountered in the current study was the fact that the human plasma did not form a clot when a Ca 21 ion solution was added; in contrast, a clot had been formed with only this Ca 21 ion addition in the previous study's bovine case. After noting the absence of a clot, we added a bovine thrombin solution at 1 NIH unit/mL and obtained successful clot formation. Bovine thrombin has long been used as an efficient human hemostatic drug problem, 36 because it has the same mechanism as human thrombin in introducing human blood thrombosis, and is more easily available as a commercial product. We observed that a clot sufficiently stiff for the spectroscopic measurement was obtained with this thrombin addition. Because of possible variations between product lot numbers of human plasma, we resolved to identify the appropriate amount of thrombin addition for clot formation in each product lot number of human plasma. In our current examinations for two lots of human plasma, we found that fibrin clots were successfully obtained at 1 NIH unit/mL of thrombin. This thrombin concentration may be varied for the application of the sheet-type fibrin clot preparation to various plasma lots.
Regarding a clot's calibration curve, we compared the three measurements shown in Figure 9A . On the xaxis of Figure 9A , a gap distance between the two PS films is plotted. The optical density of a clot (black plots) in the calibration chamber was observed to increase in a gap-distance-dependent manner with a vertical intercept at 0.05. We measured two blank controls: one was filled with distilled water and the other was a calibration chamber only. (We filled the gap with air.) The distilled-water-filled chamber (red plots) showed a constant and lower optical density than that of the chamber only (blue plots). This difference indicates two points: First, that the chamber itself exhibited considerable optical density possibly because of the reflection at the PS film's interfaces; and second, that reflection at the interface between the air and the PS film was greater than at the interface between the water and the PS film. We believe that the subtraction of the distilled-waterfilled chamber's optical density from the clot-filled chamber's optical density helped to obtain pure opticaldensity values of the clot, because both the black plots and the red plots in Figure 9A had the same vertical intercept. We obtained a calibration curve between clot thickness and optical density at 560 nm by performing this subtraction, as shown in Figure 9B . This calibration curve exhibited a good linear relationship between these two measured values to a high degree in a range between 0.05 and 2.5 mm of clot thickness. This calibration curve was highly reproducible for one lot of human plasma. We took note of this finding, and in a measurement of a sample clot for the sonothrombolysis assay, we subtracted an optical-density value of 0.035 from the measured optical-density values of the clot samples. This value (0.035) was obtained with a cell that involved a PS film (50-lm thick) covered with water (approximately 1.5-mm thick). (There was a water-PS film interface in this case.) We confirmed that, at 560 nm, the optical density (0.044) of the sample cell possessing only a PS film (an air-PS film interface in this case) was greater than the optical density (0.035) of the sample cell possessing a PS film and water. Our established method for measuring clot thickness does not require that attached fluid be wiped off the surface of a clot before each measurement; therefore, our method runs no risk of a wipe-off error-a risk that is involved in conventional methods measuring a clot mass. Figure 10A shows a typical result of sonothrombolysis measurements in the new assay method involving the use of Probe A for 4.5 W/cm 2 irradiation at the center of the cell. For two measured values (presonication clot thicknesses and postsonication clot thicknesses) and one calculated value (lysis length, which is the difference when the postsonication thickness is subtracted from the presonication thickness), we scanned in one direction to draw each of the four lines, as illustrated in Figure 3B . The four lines almost overlapped each other for all of the values. This fact indicates that the prepared clot was almost free of air bubbles and flat, and that thrombolysis proceeded almost in a distortion-free manner because of the well-designed cell for the sonothrombolysis measurements. The ultrasound intensity of Probe A was almost zero for the positions between 4.0 and 6.0 mm from the cell center. Therefore, we limited our measurements to an area within 6 mm of the cell center. In preparations of clots, we observed a considerable variation in thickness in each lot of clots. When we used the standard 1.5-mm-thick silicone insert, we obtained clot thicknesses of between 1.2 and 1.5 mm. This variation in thickness did not pose any problem in Figure 10A and D) with high reproducibility. This flatness may be favorable for accurate analyses of sonothrombolysis. Figure 10B presents the averages of Figure 10A 's four lysis-length plots. The largest change in clot thickness took place at the center of the clot, whereas smaller changes were observed between the 4-mm point and the 6-mm point. Figure 10B plots the ultrasound's field strength measured with a hydrophone. (This plot was obtained at the clot position with the cell lacking a PS film.) By comparing these two plots in Figure 10B , we confirmed that ultrasound irradiation provided the enhancing effect of thrombolysis, because both of the plots exhibit their maximum values at the center and minimum values at 4.5 mm from the center. Because ultrasound intensity was almost zero at the position 4.5 mm from the center, we concluded that the activity of the rt-PA was the sole cause of the thrombolysis at this position. To obtain a closer relationship between the two plots, we drew a new figure, Figure 10C , using Figure 10B 's plots in an area 4.5 mm from the center. Figure 10C plots the ultrasound's field intensity and the lysis length on the horizontal axis and on the vertical axis, respectively. Figure 10D shows the average thicknesses of the rt-PA only case (no ultrasound irradiation). In this case, we observed almost no difference between the center of the clot cell and the peripheral position of the cell within 6 mm of the cell center. This fact confirms the enhancement effect that ultrasound has on thrombolysis, as seen in Figure 10A .
Evaluation of Sonothrombolysis
In the next step, we analyzed the thrombolysisenhancement effect using both the common field strength of ultrasound for the sonothrombolysis and the other ultrasound probe (Probe B). Probe B would exhibit a wider sonic irradiation field than Probe A-an outcome that is advantageous in sonothrombolysis therapy. First, we examined a sonic strength value of 0.70 W/cm 2 , because 0.72 W/cm 2 is the clinically used safety standard for diagnostic uses involving ultrasound that has a frequency of 2 MHz or higher. The two most famous clinical sonothrombolysis trials (2 MHz for Alexandrov et al Although it has not been clinically confirmed whether this diagnostic safety standard can be applied to therapeutic ultrasound sonication with a frequency less than 2 MHz, we assume that 0.70 W/cm 2 is appropriate as the maximum examined intensity in our experiments. Then, we performed the thrombolysis experiments at 0.70 and 0.30 W/cm 2 , and Figure 11A and B presents the results. Figure 11A illustrates the lysis behavior in terms of the average values of the 4-direction measurements at 0.70 W/cm 2 and the 60-min irradiation period. We clearly observed the enhanced lysis at the clot's center position. Furthermore, we wanted to measure sonothrombolysis with an ultrasound field weaker than 0.70 W/cm 2 . In this regard, Figure 11B presents the results of the 0.30 W/cm 2 and 120-min irradiation case. In the cases with the 0.30 W/cm 2 setting, we prepared a clot thickness (approximately 1.8 mm) greater than the standard thickness. To achieve this objective, we placed a silicone insert between a PP film and a propping bar (as shown in Figure 2C ), making sure that the insert was thinner (1.0-mm thick) than the standard 1.5-mm-thick silicone insert shown in Figure 2C . This is because the lysis length with rt-PA may equal the thickness (between 1.2 and 1.5 mm) of the standard clot for a long incubation period (120 min), even in the absence of sonication. After dealing with the insert, we used the 4-mm-deep cell to set this thicker clot. We maintained good flatness for the thicker clot, as shown in the black plots of Figure  11B . The ultrasound's enhancement of clot lysis was less impressive than in the 0.70 W/cm 2 case, but was still measurable even with such weak ultrasound intensity (0.30 W/cm 2 ) insofar as the lysis lengths at positions near the center were larger than the lysis lengths at peripheral positions approximately 4 mm from the center. Figure 11C compares the sonothrombolysis effects in various conditions (ultrasound power and irradiation period) by presenting enhanced lysis length and an enhanced ratio. Figure 11A shows that Probe B exhibited measurable ultrasound intensity at approximately 0.15 W/cm 2 at 6 mm from the center. In contrast, Probe A used in Figure 10A , B and D, exhibited almost no intensity at the 6-mm position. Therefore, according to our evaluations, the calculated enhanced ratios for Probe B were lower than the true enhanced ratios that can be obtained in the case involving a probe whose ultrasound intensity is zero at the 6-mm position. Even in this nonideal condition, evaluation of the enhanced ratio with Probe B can facilitate comparisons between the lysis enhancement and ultrasound intensity in relation to various ultrasound strengths (0.3 and 0.7 W/cm 2 ) and various sonication durations (30, 60 , and 120 min), as shown in Figure 11C and D. Figure 11C plots the 0.70 W/cm 2 sonication cases with the average 6 standard deviation of the four (or sometimes five) measurements we carried out. The enhanced lysis length was found to be almost proportional to the sonication period, whereas the enhanced ratio was constant for the 30-min sonication case and the 60-min sonication case. Interestingly, in the "rt-PA only" cases (no-sonication cases), we observed small negative calculated enhanced lysis lengths. These negative values indicate that rt-PA exhibited slightly higher lysis activity at the 6-mm peripheral position than at the center of the clot. The negative lysis length values were greater at positions between 6 and 15 mm from the center (data not shown). Presently, we have not elucidated the reason for the higher activity of this rt-PA at the peripheral positions. If we assume that this higher rt-PA's activity at the peripheral part of the clot also works in the sonication cases, actual enhanced ratios may be a little higher that those measured. Figure 11D shows each measurement datum for the 0.30 W/cm 2 sonication. Sonication at 0.30 W/cm 2 provided measurable enhancement effects that ultrasound irradiation had on thrombolysis, and we observed negative values in the "rt-PA only" cases (no-sonication cases) in the same manner as observed in Figure 11C . We think that elucidation of the reason for the negative values' appearance in the "rt-PA only" cases is important, and that improvements for diminishing these negative values may help to raise the sensitivity of this method for a lower ultrasound intensity such as 0.1 W/cm 2 . Finally, we compared our method with a conventional mass-loss method by focusing on "wipe-off" errors in measurements. We prepared a small mass of fibrin clot (approximately 100 mg) in the clot cell shown in Figure 2A , and then incubated the clot in an rt-PA solution in the same conditions as those for the sheet-type measurements, except this time we used a shorter incubation period (15 min). Before and after this incubation in rt-PA, we measured the clot's weight 3 times. Results indicated a large variance in weight: The average 6 standard deviation (S.D.) was 71.6 6 8.3 mg for a clot before the rt-PA incubation and 44.0 6 10.0 mg for a clot after the rt-PA incubation. In contrast, our method provided much smaller variance in spectrophotometric thickness measurements: The average 6 S.D. of optical density was 0.1449 6 0.0005 for pre-rt-PA incubation and 0.0989 6 0.0003 for post-rt-PA incubation. These results also indicate that our method brought about a level of lysis measurement similar to the level associated with the conventional mass-loss method: 31.7% reduction of weight in our method and 38.5% reduction of weight in the mass-loss method in similar rt-PA incubation conditions. When a ratio of S.D. to the average was calculated, the ratio was 11.6 and 22.7% for pre-and post-rt-PA incubation for the mass clot, whereas the ratio was much smaller for the sheet-type clot: 0.3% and 0.4% pre-and postincubation, respectively. The large variances for the mass method indicate the significant effect of wipe-off errors on weight measurements, and the variance became larger in the postincubation measurement-possibly because of the smaller weight values as well as to the more labile and less resistant (to the wipe-off procedure) properties of the postincubation clot. These comparisons clearly indicate that we conducted highly repeatable measurements in our new sheet-type method, because our method has the advantage over the conventional clot-mass method of being free from the wipe-off error.
Discussion
In this paper, we have established a new and easy method for in vitro ultrasonic thrombolysis assays using a sheet-type human fibrin clot. Because of the spectroscopic measurement, our method is free from "wipe-off" errors encountered in the clot-mass measurement method. As compared with previously reported photometric methods, our method possesses the following critical advantage. The previous photometric methods' evaluation of sonothrombolysis is dependent on the size and shape of clots; in contrast, every measurement of our proposed method yields only a one-dimensional measurement value (ie, the "decrease in clot thickness" value). Therefore, our method can be a useful in vitro assay method in which comparisons among many experimental conditions are much more easily made than in the previous methods, although the need for a custommade spectrophotometer is a current problem of our method. Additionally, in our method we can easily obtain the correlations between thrombolysis enhancements and ultrasound field strength, because of the many data points measured in one time scan. As shown in Figure 10C , we can analyze the relationship between lysis length and ultrasound intensity with only one timescanning measurement lasting only approximately 2 min. This is a big advantage of our method over many previously reported methods of sonothrombolysis measurements.
Petit et al 32 reported an assay method that could analyze many data points in one time experiment. In their method, the correlations between thrombolysis enhancements and ultrasound field strength could be obtained in one time measurement. However, the aforementioned researchers obtained thrombolysis enhancements for human whole blood clots only in the presence of both rt-PA and microbubbles. An "rt-PA only" condition with strong sonication (an acoustic pressure of 1,000 kPa, and an average intensity of 11 W/cm 2 ) could not provide thrombolysis enhancement. In contrast, in our system, we were able to measure the enhancement effects with rt-PA only and in a considerably mild ultrasound irradiation condition at 0.30 W/cm 2 , which is below the safety standard for diagnostic ultrasound uses, although our examined clots were fibrin clots, not whole blood clots. In future research, we would like to examine whether our method can exhibit higher sensitivity than Petit et al's method using human whole blood clots. However, C.K. Holland groups reported measurements of thrombolysis enhancement using 120-kHz ultrasound at 0.47 W/cm 2 (Shaw et al 37 ) and at 1.0 W/cm 2 (Bader et al 38 ). Our method showed similar sensitivity to the C.K. Holland group's method, although there is a difference in clot types: We used fibrin clots, and the C.K. Holland group used whole blood clots.
Previously, we reported 39 that ultrasound irradiation at 0.30 W/cm 2 did not exhibit any harmful effects on middle-cerebral-artery-occluded spontaneously hypertensive rats having received rt-PA injection. Therefore, sonothrombolysis measurements for 500 kHz at this mild intensity range are meaningful.
Another critical advantage of our assay method involves the issue of standing waves. If standing waves form in measurement environments for sonothrombolysis, stronger spots and weaker spots of standing waves may cause errors in sonothrombolysis measurements. The distance between a stronger spot and a weaker spot is a quarter of a wavelength of the irradiated ultrasound when ultrasound enters a flat surface vertically. In this paper, we call this distance the standing wave distance. In our case of the use of 500 kHz ultrasound, the standing-wave distance was 0.7 mm. We prepared fibrin clots in a thickness range between 1.2 and 1.8 mm, and the measured thickness decreased in a range between 0 and 1.0 mm. In these ranges, a 0.7-mm distance is small enough to affect sonothrombolytic activity at the clot surface where the lysis is advancing. For example, in the presence of a standing wave with a 0.7-mm distance between a stronger spot and a weaker spot, the following situation may arise: Because clot lysis is very active for 1.8-mm thicknesses but is very inactive for 1.1-mm thicknesses, the emergence of the standing waves makes it impossible to obtain close relationships between thrombolysis behaviors and ultrasound conditions if the "sizes" of measurements (eg, sizes of clots and sizes of decreases in clot thickness) are comparable to or smaller than the standing-wave distance. Sonothrombolysis may be enhanced specifically at the bright stripes or dark stripes of Schlieren images in a mechanism-dependent manner. If ultrasound's acoustic pressure is a dominant factor influencing sonothrombolysis enhancement, the enhancement can be obtained specifically at dark stripes, and if the change rate of acoustic pressure is a dominant influencing factor, the enhancement can be obtained specifically at bright stripes. Presently, we do not know which is the dominant influencing factor. In both of the mechanism cases, however, the generation of standing waves is an undesirable circumstance for accurate measurements of sonothrombolysis enhancement, because rates of thrombolysis may change according to the different positions of clots. Evasion of standing waves' generation is desirable for accurate assays of sonothrombolysis. Therefore, we believe that our new method is of great importance in this field of research because the method is free of standing waves' effects.
However, we recognize that an apparent disadvantage accompanying our method is its reliance on a custom-made spectrophotometer.
All of these results clearly demonstrate the ease of use and effectiveness of the new assay method. In the present study, we observed enhancements in rt-PA's thrombolytic activity through ultrasound irradiation at ultrasound intensities of 0.70 and 0.30 W/cm 2 . Even though our sheet-type clots are very different in shape from clots found in cerebral arteries in vivo, our method with sheet-type clots can contribute to developments of sonothrombolysis through optimization of various ultrasound-irradiation conditions in vitro. In the current assay system, we did not measure cavitation. Additionally, we examined only fibrin clots, not whole blood clots. Examinations on whole blood clots must be done in the next step. In the future, we plan to use this method to examine sonothrombolytic mechanisms and, specifically, the effects of other ultrasound conditions (eg, frequency, duty cycle, modulation) on sonothrombolytic activity.
In conclusion, we successfully established an in vitro sonothrombolysis assay method based on spectrophotometric measurements of clot thickness. Our proposed method contains some weak points (eg, its reliance on a custom-made spectrophotometer, and the absence of any cavitation measurement); nevertheless, the method is highly useful for optimizing ultrasound's irradiation conditions in the context of sonothrombolysis.
